Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.

[1]  M. Quinn,et al.  The impact of PET/CT in the management of recurrent ovarian cancer. , 2006, Gynecologic oncology.

[2]  E. Hauth,et al.  Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. , 2005, European journal of radiology.

[3]  R. Wahl,et al.  Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. , 2005, Gynecologic oncology.

[4]  Barry A. Siegel,et al.  Oncologic PET/CT: current status and controversies , 2005, European radiology.

[5]  Wolfgang A Weber,et al.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Nanni,et al.  (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  F. Fazio,et al.  Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. , 2004, Radiology.

[8]  Elliot K Fishman,et al.  Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. , 2003, Gynecologic oncology.

[9]  S. Reske,et al.  Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. , 2002, Radiology.

[10]  C. Meltzer,et al.  Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. , 2002, Gynecologic Oncology.

[11]  E. Yoshikawa,et al.  Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  C. Pomel,et al.  Cytoreductive surgery for advanced stages of ovarian cancer. , 2000, Seminars in surgical oncology.

[13]  M. Tuxen,et al.  Use of CA 125 in follow-up of ovarian cancer , 1996, The Lancet.

[14]  S. Cannistra.  Cancer of the ovary. , 1993, The New England journal of medicine.

[15]  T. Yen,et al.  Positron emission tomography in gynecologic cancer. , 2006, Seminars in nuclear medicine.

[16]  Wolfgang A Weber,et al.  Monitoring response to treatment in patients utilizing PET. , 2005, Radiologic clinics of North America.

[17]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[18]  David W Townsend,et al.  PET/CT today and tomorrow. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  F. Jänicke,et al.  Metabolische Charakterisierung von Ovarialtumoren mit der Positronen-Emissions-Tomographie und F-18-Fluordeoxyglukose , 1997 .

[20]  R. Graziano,et al.  Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan. , 1995, European journal of gynaecological oncology.